BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

This study uses biomarkers — biological measurements from blood and tumor tissue — to find the best sequence and combination of treatments before surgery (neoadjuvant therapy) for people with HER2-positive breast cancer. HER2-positive means the cancer cells have too many copies of a protein called HER2, which fuels tumor growth. **You may be eligible if...** - You are 18 years old or older - You have been diagnosed with HER2-positive invasive breast cancer (confirmed within 90 days) - Your cancer is also confirmed to be the HER2-enriched subtype by a gene expression test - You are in good general health (ECOG performance status 0–2) **You may NOT be eligible if...** - Your breast cancer is not HER2-positive or HER2-enriched subtype - You have already started treatment for this breast cancer - You have had a prior cancer within the last 5 years (except certain early-stage skin cancers) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.